TICE BCG
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $79,320 | 1 | 0 |
| 2022 | $10.0M | 37 | 0 |
| 2021 | $5.5M | 31 | 0 |
| 2020 | $94,242 | 2 | 0 |
| 2019 | $268,747 | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.0M | 82 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 | Merck Sharp & Dohme LLC | $9.9M | 0 |
| A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 | Merck Sharp & Dohme Corporation | $5.3M | 0 |
| A PHASE III RANDOMIZED TRIAL TO EVALUATE THE INFLUENCE OF BCG STRAIN DIFFERENCES AND T CELL PRIMING WITH INTRADERMAL BCG BEFORE INTRAVESICAL THERAPY FOR BCG-NA VE HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER | Merck Sharp & Dohme Corporation | $360,476 | 0 |
| A PHASE III RANDOMIZED TRIAL TO EVALUATE THE INFLUENCE OF BCG STRAIN DIFFERENCES AND T CELL PRIMING WITH INTRADERMAL BCG BEFORE INTRAVESICAL THERAPY FOR BCG-NA E HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER | Merck Sharp & Dohme Corporation | $219,898 | 0 |
| A PHASE III RANDOMIZED TRIAL TO EVALUATE THE INFLUENCE OF BCG STRAIN DIFFERENCES AND T CELL PRIMING WITH INTRADERMAL BCG BEFORE INTRAVESICAL THERAPY FOR BCG-NA E HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER | Merck Sharp & Dohme LLC | $148,431 | 0 |
| Phase I Study of MK-3475 in Combination with BCG for Patients with High Risk Superficial Bladder Cancer | Merck Sharp & Dohme Corporation | $2,513 | 0 |
| A Phase I single site open label clinical trial for the development of a human BCG challenge model to assess TB drugs and vaccines | Merck Sharp & Dohme LLC | $1,571 | 0 |
Top Doctors Receiving Payments for TICE BCG
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $16.0M | 82 |
Manufacturing Companies
- Merck Sharp & Dohme LLC $10.0M
- Merck Sharp & Dohme Corporation $5.9M
Product Information
- Type Biological
- Total Payments $16.0M
- Total Doctors 0
- Transactions 82
About TICE BCG
TICE BCG is a biological associated with $16.0M in payments to 0 healthcare providers, recorded across 82 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2023. In 2023, $79,320 was paid across 1 transactions to 0 doctors.
The most common payment nature for TICE BCG is "Unspecified" ($16.0M, 100.0% of total).
TICE BCG is associated with 7 research studies, including "A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676" ($9.9M).